Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Long-Term Deferred Tax for 8 consecutive years, with $113.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Deferred Tax rose 9.03% year-over-year to $113.8 million; the trailing twelve-month figure through Jun 2026 stood at $113.8 million (up 9.03% YoY), and the FY2025 full-year result was $126.0 million, up 7.8% from the prior year.
• Long-Term Deferred Tax retreated to $113.8 million in Q2 2026 per ALNY's latest filing, from $117.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $126.0 million in Q4 2025 and bottomed at $10.1 million in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $99.2 million across 4 years, with a median of $110.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax surged 1056.94% in 2024, then increased 7.8% in 2025.
• Over 4 years, Long-Term Deferred Tax stood at $10.1 million in 2023, then soared by 1056.94% to $116.9 million in 2024, then advanced by 7.8% to $126.0 million in 2025, then dropped by 9.67% to $113.8 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $113.8 million, $117.0 million, and $126.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.